Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Chun-ling Dai, Amit K. Tiwari, Chung-Pu Wu, Xiao-dong Su, Si-Rong Wang, Dong-geng Liu, Charles R. Ashby, Jr., Yan Huang, Robert W. Robey, Yong-ju Liang, Li-ming Chen, Cheng-Jun Shi, Suresh V. Ambudkar, Zhe-Sheng Chen, and Li-wu Fu

Abstract

Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2. It is conceivable that lapatinib may inhibit the function of ATP-binding cassette (ABC) transporters by binding to their ATP-binding sites. The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters. Our results showed that lapatinib significantly increased the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was observed in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells. Lapatinib alone, however, did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in sensitive and resistant cells. Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E2173G by ABCG2. Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [125I]iodoarylazidoprazosin in a concentration-dependent manner. However, lapatinib did not affect the expression of these transporters at mRNA or protein levels. Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice. Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function. These findings may be useful for cancer combination therapy with lapatinib in the clinic. [Cancer Res 2008;68(19):7905–14]

Introduction

Multidrug resistance (MDR) is a major obstacle to successful chemotherapy treatment. MDR often results due to overexpression of ATP-binding cassette (ABC) transporters. In the human genome, 48 different ABC transporters have been identified and are divided into seven subfamilies (A-G) based on sequence similarities (1). Thus far, the major members of the ABC transporters leading to MDR in cancer cells include ABC subfamily B member 1 (ABCB1; also called P-glycoprotein), ABC subfamily C members (ABCCs, MDR-associated proteins), and ABC subfamily G member 2 (ABCG2; also called breast cancer resistance protein, mitoxantrone resistance protein, and placenta-specific ABC transporter). These membrane proteins actively pump out a wide range of structurally and functionally diverse amphipathic anticancer drugs from the inside of tumor cells, thereby decreasing their intracellular drug accumulation and resulting in chemotherapeutic drug resistance (1–4). Furthermore, each transporter can translocate unique compounds in addition to some overlapping substrates (1). Drugs transported by ABCB1 include hydrophobic compounds, either uncharged or slightly positively charged, including most chemotherapeutic agents such as Vinca alkaloids, anthracyclines, epipodophyllotoxins, and taxanes (5). A few of the ABC subfamily members have been shown to confer MDR to organic anion compounds and phase II metabolic products, as well as some natural product chemotherapeutic agents, antifolates, and nucleotide analogues (6). The spectrum of chemotherapeutic agents transported by ABCG2 includes anthracyclines, mitoxantrone, camptothecin-derived and indolocarbazole topoisomerase I inhibitors, methotrexate, and flavopiridol (7).

The ErbB/Her family of receptor tyrosine kinases mediates the transphosphorylation of tyrosine residues in the cytoplasmic domain of tyrosine kinase receptors via homodimerization or heterodimerization on ligand activation (8). In human tumors, the epidermal growth factor receptor (EGFR; Her-1 or ErbB1) and the other three members of the EGFR family, human epidermal receptor type 2, 3, and 4 (Her-2, Her-3, and Her-4), are often overexpressed, dysregulated, or mutated, and these abnormal alterations of EGFR activate a series of intracellular protein kinase signaling pathways, such as the Ras/mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase, signal transducer and activator of transcription, protein kinase C, and phospholipase D pathways, promoting tumor growth and progression including the promotion of proliferation, angiogenesis, invasion, metastasis, and inhibition of apoptosis (8, 9). Therefore, blockade of EGFR and/or Her-2 activation may be able to suppress cancer cell growth and...
progression. Lapatinib (Tykerb, GW572016) is an orally active small molecule, which is a novel member of the family of kinase inhibitors that inhibits the tyrosine kinases of Her-2 and EGFR. In preclinical studies, lapatinib was not cross-resistant to trastuzumab (10, 11). In clinical studies, lapatinib in combination with capecitabine has shown promising results compared with capecitabine alone in a phase III trial of Her-2–positive metastatic breast cancer patients whose cancers become unresponsive to trastuzumab or to other therapies (12). Lapatinib in combination with tamoxifen effectively increased cell proliferation and restored tamoxifen sensitivity in estrogen receptor–positive breast cancer models with shown resistance to tamoxifen (13, 14). Several randomized phase I and II studies (EGF104383, EGF104535, EGF30001, EGF105767, EGF100161, and EGF1025801) are ongoing to compare paclitaxel/docetaxel plus lapatinib as first-line treatment for Her-2–overexpressing breast cancer patients. But the action and mechanisms underlying the lapatinib-induced chemosensitivity of conventional chemotherapeutic agents in cancer cells remain to be elucidated. Gefitinib, an inhibitor of the tyrosine kinase activity of Her-1, has been reported to interact with ABCG2 and ABCB1 and to reverse ABCB1– and/or ABCG2-mediated MDR by directly inhibiting their drug pump function in cancer cells (15). Furthermore, ABCG2-transduced cells were found to be resistant to gefitinib (16), and expression of ABCG2, but not its nonfunctional mutant, protects EGFR signaling–dependent tumor cells from death on exposure to gefitinib, and this protection was reversed by the ABCG2-specific inhibitor Ko143 (15). These reports strongly suggested that ABCG2 can actively pump gefitinib out of the cells. In our previous study, we also found that erlotinib was also able to antagonize ABCB1- and ABCG2-mediated MDR, suggesting that it might be a substrate of these two transporters (17). Lapatinib is also a potent and reversible inhibitor that acts at the ATP-binding site of the tyrosine kinase domains of both EGFR and Her-2. It is conceivable that lapatinib may inhibit functions of ABC transporters by binding to their ATP-binding sites. These have spurred efforts to investigate whether lapatinib can enhance the efficacy of conventional chemotherapeutic drugs via interaction with ABC transporters in MDR cancer cells and tumor xenograft model.

Materials and Methods

Materials. [125I]idoarlylazidoprazosin (IAAP; 2,200 Ci/mmol) and [3H]-ethyl-17β-estradiol (40.5 Ci/mmol) were obtained from Perkin-Elmer Life Sciences. [3H]Mitoxantrone (4 Ci/mmol) and [3H]methotrexate (23 Ci/mmol) were purchased from Moravek Biochemicals, Inc. Lapatinib and topotecan were products of Glaxo Smith Co. Erlotinib was purchased from Chemie Tek, Inc. DMEM and RPMI 1640 were products of Life Technologies. Monoclonal antibody C-219 (against ABCB1) was supplied by the Signet Laboratories, Inc. Monoclonal antibodies including ABCB1, ABCG2, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were products of Santa Cruz Biotechnology, Inc. Anti-MAPK1/2 (Erk1/2), phosphorylated extracellular signal-regulated kinase, and phosphorylated Akt antibodies were purchased from Kangchen Co. Akt antibody was a product of Cell Signaling Technology, Inc. R-phycocerythrin (PE)-conjugated mouse monoclonal anti-human EGFR antibody and mouse IgG2b isotype control were obtained from BD Biosciences. PE-conjugated mouse monoclonal anti-human Her-2 antibody and mouse IgG2b isotype control were from R&D Systems. Fumitremorgin C (FTC) was synthesized by Thomas McCloud (Developmental Therapeutics Program, National Products Extraction Laboratory, NIH, Bethesda, MD). Doxorubicin, paclitaxel, mitoxantrone, 6-mercaptopurine, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), rhodamine 123, and other chemicals were obtained from Sigma Chemical Co.

Cell lines and cell culture. The following cell lines were cultured in essential medium containing 10% fetal bovine serum at 37°C in the presence of 5% CO2: the human breast carcinoma cell line MCF-7 and its doxorubicin-selected derivative ABCB1-overexpressing MCF-7/adr (18), the human epidermoid carcinoma cell line KB and its vincristine-selected derivative ABCB1-overexpressing KB/200 (19), and the colon carcinoma cell line SW1 and its mitoxantrone-selected derivative ABCG2-overexpressing SW1-M1-80 (20). HEK293/pCDNA3.1, ABCG2-482-R5, ABCG2-482-G2, and ABCG2-482-T7 cells were established by selection with G418 after transfecting HEK293 with either empty pcDNA3.1 vector or pcDNA3.1 vector containing full-length ABCG2 coding either arginine (R), glycine (G), or threonine (T) at amino acid 482 position, respectively, and were cultured in medium with 2 mg/mL G418 (21). All cells were grown in drug-free culture medium for >2 wk before assay.

Cytotoxicity assay. The MTT assay was used to access cytotoxicity (22, 23). In detail, cells were grown in 96-well microtiter plates. To determine the toxicity of lapatinib, various concentrations of lapatinib diluted with medium were added into the wells. To test the effect of lapatinib on the chemosensitivity of cancer cells, lapatinib was added to the medium with various concentrations of doxorubicin in MCF-7, MCF-7/adr, and MX, or topotecan in SW1 or SW1-M1-80 cells, respectively, and mitoxantrone and cisplatin in HEK293/pCDNA3.1, ABCG2-482-R5, ABCG2-482-G2, and ABCG2-482-T7 cells. The concentrations required to inhibit growth by 50% (IC50) were calculated from survival curves using the Bliss method (24). The degree of resistance was calculated by dividing the IC50 for the MDRI cells by that of the parental sensitive cells. The degree of the reversal of MDR was calculated by dividing the IC50 for cells with the antinecancer drug in the absence of lapatinib by that obtained in the presence of lapatinib.

Experimental animals. Athymic nude mice, 5 to 6 wk old and weighing 18 to 23 g (Center of Experimental Animals, Sun Yat-Sen University), were used for the KBv200 cell xenografts. All animals were provided with sterilized food and water.

MDR human carcinoma xenografts. The KBv200 cell xenograft model was established as described by Chen and colleagues (25). Briefly, KBv200 cells grown in vitro were harvested and implanted s.c. under the shoulder in nude mice. When the tumors reached a mean diameter of 0.5 cm, the mice were randomized into four groups and treated with one of the following regimens: (a) saline (q3d × 4), (b) paclitaxel (18 mg/kg, i.p., q3d × 4), (c) lapatinib (100 mg/kg, p.o., q3d × 4), and (d) paclitaxel (18 mg/kg, i.p., q3d × 4) + lapatinib (100 mg/kg, p.o., q3d × 4, given 1 h before giving paclitaxel). The body weight of the animals was measured every 3 d to adjust the drug dosage. The two perpendicular diameters (A and B) were recorded every 3 d and tumor volume (V) was estimated according to the following formula (25):

\[
V = \frac{\pi}{6}(A + B)^{2} \times \frac{1}{2}
\]

The curve of tumor growth was drawn according to tumor volume and time of implantation. The mice were anesthetized and killed when the mean of tumor weights was over 1 g in the control group. Tumor tissue was excised from the mice and weighted. The rate of inhibition (IR) was calculated according to the following formula (25):

\[
IR(\%) = 1 - \frac{\text{Mean tumor weight of experimental group}}{\text{Mean tumor weight of control group}} 	imes 100\%
\]

Doxorubicin and mitoxantrone accumulation. The intracellular doxorubicin accumulation in ABCB1-overexpressing MCF-7/adr cells and their parental sensitive MCF-7 cells was examined by flow cytometry (26). The logarithmically growing cells were treated with 0.625, 1.25, or 2.5 μmol/L of lapatinib at 37°C for 3 h. Then, 10 μmol/L doxorubicin was added to the medium and the incubation continued for another 3 h. The cells were then collected, centrifuged, and washed twice with cold PBS containing 10 μmol/L verapamil. Cells were resuspended in 200 μL PBS

\[\text{Cancer Research} \quad \text{Cancer Res 2008; 68: (19). October 1, 2008} \quad 7906 \quad \text{www.aacrjournals.org}\]

Downloaded from cancerres.aacrjournals.org on July 22, 2017. © 2008 American Association for Cancer Research.
and then analyzed by flow cytometry (Elite, Beckman Coulter), with an excitation wavelength of 488 nm (argon laser) for the mean fluorescence intensity (MFI) of intracellular doxorubicin. The relative value of drug accumulation was identified by dividing the MFI for each measurement by that of the ABCB1-expressing cells in the absence of lapatinib.

The accumulation of mitoxantrone in ABCG2-transfected cells was measured using [3H]mitoxantrone. Confluent cells in 24-well plates were preincubated with or without lapatinib for 1 h at 37°C. To measure drug accumulation, the cells were then incubated with 0.2 µmol/L [3H]mitoxantrone for 2 h in the presence or absence of lapatinib at 37°C. After washing thrice with ice-cold PBS, the cells were typsinized and lysed in 10 mmol/L lysis buffer (pH 7.4, containing 1% Triton X-100 and 0.2% SDS). Each sample was placed in scintillation fluid and radioactivity was measured using a Packard Tri-Carb 1900CA liquid scintillation analyzer from Packard Instrument Company, Inc.

Preparation of membrane vesicles and total cell lysates. Membrane vesicles were prepared by the nitrogen cavitation method as previously described (17, 27). Vesicles were stored at −80°C until ready for use. To prepare the total cell lysates, cells were harvested and rinsed twice with PBS. Cell extracts were prepared with radioimmunoprecipitation assay buffer (1× PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 100 µg/mL phenylmethylsulfonyl fluoride, 10 µg/mL aprotinin, 10 µg/mL leupeptin) for 30 min with occasional rocking and clarified by centrifugation at 12,000 × g for 4°C for 15 min. The supernatant containing total cell lysates was stored at −80°C until it was ready for use. The protein concentration was determined by Bradford method. High Five insect cells (Invitrogen) were infected with the recombinant baculovirus carrying the human ABCB1 or ABCG2 cDNA with a His tag at the COOH-terminal end (BV-MDR1(His 6)) or (BV-(His 6)-G). Reactions were carried out for ABCB1, ABCG2, and GAPDH at 94°C for 2 min for initial denaturation and then at 94°C for 30 s, 56°C for 30 s, and 72°C for 1 min. After 35 cycles of amplification, additional extensions were done at 72°C for 10 min. Products were resolved and examined by 2% agarose gel electrophoresis (24).

Western blot analysis. To determine whether lapatinib affects the expression of ABCB1 or ABCG2, the cells were incubated with different concentrations of lapatinib for 48 h. To test whether lapatinib is able to block Akt or Erk1/2 phosphorylation, we incubated cells with different concentrations of lapatinib (0.625–2.5 µmol/L) for different periods (12–48 h). Then, the cells were harvested and rinsed twice with PBS. Cell extracts were prepared by incubating with buffer (1× PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 100 µg/mL phenylmethylsulfonyl fluoride, 10 µg/mL aprotinin, 10 µg/mL leupeptin) for 30 min with occasional rocking and clarified by centrifugation at 12,000 × g for 15 min at 4°C. Identical amounts (100 µg protein) of cell lysates were incubated at 37°C for 20 min and resolved by SDS-PAGE and electrophoretically transferred onto polyvinylidene difluoride membranes. After being incubated in blocking solution containing 5% nonfat milk in TBST buffer (10 mmol/L Tris-HCl [pH 8.0], 150 mmol/L NaCl, 0.1% Tween 20) for 1 h at 4°C, membranes were incubated with the appropriately diluted primary antibody. The expression of GAPDH was used as a loading control. The membranes were then incubated for 1 h with horseradish peroxidase–conjugated secondary antibody at 1:1,000 dilution. Proteins were detected by the enhanced chemiluminescence detection system (Amersham). Protein expression was quantified by Scion Image software (Scion Co.; ref. 33).

Flow cytometry. Single-cell suspensions were prepared by the addition of 0.5 mol/L EDTA followed by three washes with an isotonic PBS buffer [supplemented with 0.5% bovine serum albumin (BSA)]. For EGFR flow cytometric analysis, −1 × 10⁶ MCF-7, MCF-7/adr/S1, and S1-M1-80 cells (100 µL) were incubated at 4°C for 45 min with 20 µL of R-PE–conjugated anti-human EGFR reagent. Following this incubation, the cells were washed twice with PBS buffer (supplemented with 0.5% BSA) and the supernatant was discarded. Finally, the cells were resuspended in 400 µL PBS buffer for flow cytometric analysis. Isotype control samples were treated in an identical manner with PE-labeled mouse IgG2b antibody. For Her-2 expression analysis, 10 µL of PE-conjugated anti-human ErbB2 reagent were mixed with 25 µL of cells (4 × 10⁶/mL). After incubating for 45 min at 4°C, the cells were washed twice with PBS buffer (supplemented with 0.5% BSA) and resuspended in 400 µL PBS buffer for flow cytometric analysis. Isotype control samples were treated in an identical manner with PE-labeled mouse IgG2b antibody (34).

Statistical analysis. All experiments were repeated at least thrice and statistical significance was determined using the Student’s t test. Significance was determined at P < 0.05.

Results

Effect of lapatinib and chemotherapeutic agents in various MDR cells and their parental cells. We examined the cytotoxic
The cytotoxic effect of chemotherapeutic agents in MCF-7, MCF-7/adr, and S1-M1-80 cells in the presence of 0.625, 1.25, and 2.5 μmol/L lapatinib was tested. The mean IC_{50} values of lapatinib alone in different cell lines using the MTT assay. More than 90% of cells were viable at concentrations of lapatinib up to 2.5 μmol/L in MCF-7, MCF-7/adr, S1, and S1-M1-80 cells (Supplementary Fig. S1). In contrast, lapatinib at 10 μmol/L had virtually no cytotoxic effects on HEK293 cells (Supplementary Fig. S2). The cytotoxic effect of chemotherapeutic agents in MCF-7, MCF-7/adr, S1, and S1-M1-80 cells in the presence of 0.625, 1.25, or 2.50 μmol/L of lapatinib was tested. The mean IC_{50} values of chemotherapeutic agents in various pairs of sensitive and resistant cells in different concentrations of lapatinib are shown in Table 1. In ABCB1-overexpressing MCF-7/adr cells, lapatinib produced a significant dose-dependent increase in the cytotoxicity of doxorubicin in MCF-7/adr cells. In contrast, lapatinib only produced a ~2-fold sensitization to doxorubicin in the parental MCF-7 cells. Importantly, lapatinib, at the lowest concentration tested (0.625 μmol/L), was still able to reverse resistance to doxorubicin.

**Table 1. Effect of lapatinib on reversing ABCB1- and ABCG2-mediated drug resistance**

<table>
<thead>
<tr>
<th>Compounds</th>
<th>IC_{50} ± SD, μmol/L</th>
<th>MCF-7</th>
<th>MCF-7/adr (ABCB1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>0.334 ± 0.026 (1.0)</td>
<td>11.80 ± 2.524 (1.0)</td>
<td></td>
</tr>
<tr>
<td>+0.625 μmol/L lapatinib</td>
<td>0.148 ± 0.016 (2.3)</td>
<td>1.805 ± 0.201 (6.5)</td>
<td></td>
</tr>
<tr>
<td>+1.25 μmol/L lapatinib</td>
<td>0.062 ± 0.029 (2.1)</td>
<td>1.336 ± 0.114 (8.8)</td>
<td></td>
</tr>
<tr>
<td>+2.5 μmol/L lapatinib</td>
<td>0.155 ± 0.013 (2.2)</td>
<td>0.875 ± 0.148 (13.5)</td>
<td></td>
</tr>
<tr>
<td>+2.5 μmol/L FTC</td>
<td>0.365 ± 0.072 (0.9)</td>
<td>14.50 ± 2.57 (0.8)</td>
<td></td>
</tr>
</tbody>
</table>

S1 S1-M1-80 (ABCG2)

NOTE: Cell survival was determined by MTT assay as described in Materials and Methods. Data are the means ± SD of at least three independent experiments performed in triplicate. The fold reversal of MDR was calculated by dividing the IC_{50} for cells with the anticancer drug in the absence of lapatinib or FTC by that obtained in the presence of lapatinib or FTC.

*P < 0.05 versus that obtained in the absence of lapatinib.

**Table 2. Effect of lapatinib on reversing ABCG2-mediated resistance to mitoxantrone and cisplatin**

<table>
<thead>
<tr>
<th>Compounds</th>
<th>IC_{50} ± SD, μmol/L</th>
<th>HEK293/pcDNA3.1</th>
<th>ABCG2-482-R5</th>
<th>ABCG2-482-G2</th>
<th>ABCG2-482-T7</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>0.043 ± 0.004 (1.0)</td>
<td>0.694 ± 0.021 (1.0)</td>
<td>1.683 ± 0.004 (1.0)</td>
<td>1.060 ± 0.022 (1.0)</td>
<td></td>
</tr>
<tr>
<td>+2.5 μmol/L lapatinib</td>
<td>0.044 ± 0.003 (1.0)</td>
<td>0.177 ± 0.023 (3.9)*</td>
<td>0.219 ± 0.003 (7.7)*</td>
<td>0.192 ± 0.024 (5.5)*</td>
<td></td>
</tr>
<tr>
<td>+10 μmol/L lapatinib</td>
<td>0.047 ± 0.003 (0.9)</td>
<td>0.065 ± 0.022 (10.7)*</td>
<td>0.070 ± 0.006 (24.0)*</td>
<td>0.070 ± 0.002 (15.1)*</td>
<td></td>
</tr>
<tr>
<td>+2.5 μmol/L FTC</td>
<td>0.042 ± 0.006 (1.0)</td>
<td>0.071 ± 0.011 (9.8)*</td>
<td>0.102 ± 0.023 (16.5)*</td>
<td>0.087 ± 0.001 (12.2)*</td>
<td></td>
</tr>
<tr>
<td>+10 μmol/L erlotinib</td>
<td>0.042 ± 0.003 (1.0)</td>
<td>0.085 ± 0.002 (8.2)*</td>
<td>0.082 ± 0.001 (20.5)*</td>
<td>0.075 ± 0.004 (14.1)*</td>
<td></td>
</tr>
<tr>
<td>Cisplatin</td>
<td>1.85 ± 0.175 (1.0)</td>
<td>1.89 ± 0.240 (1.0)</td>
<td>2.05 ± 0.265 (1.0)</td>
<td>1.83 ± 0.031 (1.0)</td>
<td></td>
</tr>
<tr>
<td>+10 μmol/L lapatinib</td>
<td>2.16 ± 0.233 (0.8)</td>
<td>1.59 ± 0.252 (1.2)</td>
<td>2.16 ± 0.173 (1.0)</td>
<td>1.51 ± 0.119 (1.2)</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: Cell survival was determined by MTT assay as described in Materials and Methods. Data are the means ± SD of at least three independent experiments performed in triplicate. The fold reversal of MDR was calculated by dividing the IC_{50} for cells with the anticancer drug in the absence of inhibitor by that obtained in the presence of inhibitor.

*P < 0.01 versus that obtained in the absence of inhibitor.
at 6.5-fold in MCF-7/adr cells. When MCF-7 and MCF-7/adr cells were incubated with the specific ABCG2 inhibitor FTC at 2.5 μmol/L, we found that FTC did not significantly affect the toxicity of doxorubicin in either MCF-7 or MCF-7/adr cell lines (Table 1). This result indicated that lapatinib reverses the resistance of MCF-7/adr cells by interacting with ABCB1. Lapatinib also significantly decreased resistance to mitoxantrone and topotecan in ABCG2-overexpressing S1-M1-80 cells. In addition, a small synergetic effect was also observed for the combination of lapatinib with either topotecan or mitoxantrone in the parental S1 cells but FTC did not significantly enhance the toxic effects of mitoxantrone in parental S1 cells (Table 1). These results suggest that lapatinib strongly enhances the sensitivity of ABCB1- and ABCG2-overexpressing MDR cells to conventional chemotherapeutic agents but has only a slight effect in the parental cells.

Recent studies have shown that mutations at amino acid 482 in ABCG2 affect the substrate and antagonist specificity of ABCG2 (21, 35). Therefore, we investigated whether lapatinib would reverse ABCG2-mediated resistance to mitoxantrone in cells transfected with either the wild-type (R482) or mutant (R482G and R482T) forms of ABCG2. As shown in Table 2, the IC50 values for mitoxantrone in three ABCG2-transfected cell lines ABCG2-482-R5, ABCG2-482-G2, and ABCG2-482-T7 cells were significantly greater than those in their parental cell line HEK293/pCDNA3.1 cells. Lapatinib, at 2.5 and 10 μmol/L, significantly reduced the IC50 value for mitoxantrone and reversed resistance to mitoxantrone in cells expressing either wild-type or mutant ABCG2. In addition, the reversal effect produced by lapatinib at 10 μmol/L was similar to that of the specific ABCG2 inhibitor FTC at 2.5 μmol/L and better than that of another EGFR tyrosine kinase inhibitor (TKI) erlotinib at 10 μmol/L (Table 2). There was no significant difference in the IC50 values for mitoxantrone in the presence or absence of lapatinib in HEK293/pDNA3 cells (Table 2). In addition, lapatinib did not significantly alter the IC50 values of cisplatin, which is not a substrate of ABCG2 in any of the cell lines. These results suggest that lapatinib specifically enhances the sensitivity of ABCG2 substrates in cells expressing either wild-type or mutant R482G/T ABCG2.

**Lapatinib enhances the accumulation of chemotherapeutic agents in MDR cells overexpressing ABCB1 and ABCG2.** The results above indicated that lapatinib could enhance the sensitivity of MDR cells to certain chemotherapeutic agents. The mechanism by which this occurs is unknown. Therefore, we examined its effects on doxorubicin accumulation in ABCB1-expressing MCF-7/adr cells and parental MCF-7 cells. Figure 1A illustrates the effect of lapatinib on the accumulation of doxorubicin in the MCF-7/adr and MCF-7 cells. Doxorubicin accumulation was significantly higher (4.2-fold) in the sensitive MCF-7 cells than in the MDR MCF-7/adr cells. In contrast, the level of doxorubicin accumulation in the drug-sensitive MCF-7 cells was unaffected by 0.625, 1.25, or 2.5 μmol/L of lapatinib. In the absence of lapatinib, the level of doxorubicin accumulation was low in MCF-7/adr cells and lapatinib restored the level of doxorubicin accumulation to that of the parental cells in a dose-dependent manner. The intracellular accumulation of doxorubicin was 1.5-, 2.9-, and 3.6-fold higher in MCF-7/adr cells in the presence of 0.625, 1.25, or 2.5 μmol/L of lapatinib, respectively. As depicted in Fig. 1B, in all cells overexpressing ABCG2, lapatinib at 1 and 2.5 μmol/L produced a concentration-dependent increase in the intracellular accumulation of ³H]mitoxantrone, and the effects of lapatinib at 2.5 μmol/L were similar to that of FTC at 2.5 μmol/L. However, lapatinib did not significantly alter the intracellular accumulation of ³H]mitoxantrone in HEK293/pDNA3.1 cells. These results show that lapatinib was able to increase intracellular accumulation of chemotherapeutic agents in cells expressing ABCB1 or ABCG2.
Lapatinib inhibits the transport of \([^{3}H]\)methotrexate and \([^{3}H]\)E217/G by wild-type ABCG2. To further confirm the effect of lapatinib on the transport activity of ABCG2, we used membrane vesicles prepared from HEK293/pcDNA3 and ABCG2-482-R5 cells to perform inhibition experiments. We chose these two cell lines as the rate of ATP-dependent uptake of \([^{3}H]\)methotrexate, an antifolate anticancer drug, and a substrate of ABCG2 in membranes isolated from HEK293/pcDNA3.1 cells was significantly different from membrane vesicles of ABCG2-482-R5 cells but not from membrane vesicles of ABCG2-482-G2 and ABCG2-482-T7 cell lines (17). The effect of lapatinib on the transport of methotrexate by ABCG2 was shown in Fig. 1C. The rates of \([^{3}H]\)methotrexate uptake were significantly inhibited by lapatinib in a concentration-dependent manner. Furthermore, the inhibitory effect of lapatinib on methotrexate transport by ABCG2 membrane vesicles is comparable with that of erlotinib and FTC (Fig. 1C). In addition, lapatinib produced a concentration-dependent inhibition of \([^{3}H]\)E217/G, another substrate of ABCG2 (data not shown). These transport results suggest that lapatinib inhibits the transport of \([^{3}H]\)methotrexate and \([^{3}H]\)E217/G in wild-type ABCG2-482-R5-expressing cells.

Lapatinib activates the ATPase activity of ABCB1 and ABCG2. The drug efflux function of ABCB1 and ABCG2 is linked to ATP hydrolysis, which is stimulated in the presence of ABCB1 and ABCG2 substrates. To assess the effect of lapatinib on the ATPase activity of ABCB1 and ABCG2, we measured ABCB1- and ABCG2-mediated ATP hydrolysis using various concentrations of lapatinib under conditions that suppressed the activity of other major membrane ATPases. As shown in Fig. 2, lapatinib affected the ATPase activity of ABCB1 (Fig. 2A) and ABCG2 (Fig. 2B) in a concentration-dependent manner. Furthermore, the maximum ATPase activities of ABCB1 and ABCG2 in the presence of lapatinib were up to 42.9 ± 1.9 and 64.9 ± 1.7 nmol P_i/mg protein/min, respectively. Interestingly, lapatinib significantly stimulates the ATPase activities of ABCG2 at extremely low concentrations. This is not easily observed in Fig. 2B. Consequently, only the low concentrations of lapatinib affecting the ATPase of ABCG2 are presented in Fig. 2B (inset). These data indicated that lapatinib may be a substrate of ABCB1 and ABCG2.

Lapatinib affects the photolabeling of ABCB1 and ABCG2 with \([^{125}I]\)IAAP. ABCB1 and ABCG2 can be photolabeled by a photoaffinity analogue of prazosin, \([^{125}I]\)IAAP, and their substrates.
as well as inhibitors can compete for $^{125}\text{I}$IAAP labeling of ABCB1 and ABCG2 (32). We therefore examined the photolabeling of ABCB1 and ABCG2 with $^{125}\text{I}$IAAP by incubating membrane vesicles in the presence of various concentrations of lapatinib to primarily understand the physical interaction of lapatinib with the substrate interaction sites of ABCB1 and ABCG2. As indicated in Fig. 2, lapatinib strongly inhibited the photoaffinity labeling of ABCB1 (Fig. 2C) and ABCG2 (Fig. 2D) with $^{125}\text{I}$IAAP in a concentration-dependent manner. The concentration of lapatinib required for 50% inhibition of photolabeling of ABCB1 and ABCG2 with $^{125}\text{I}$IAAP was 2.8 ± 0.6 μmol/L and 3.2 ± 1.1 μmol/L, respectively. The results suggest that lapatinib binds to both the ABCB1 and ABCG2 substrate-binding site(s) with high affinity.

**EGFR and Her-2 status and effect of lapatinib on the blockade of Akt and Erk1/2 phosphorylation.** Using the MTT assay as an index of cytotoxicity, we observed that lapatinib alone does not produce significant cytotoxic effects in MCF-7 and S1 cell lines. However, nontoxic concentrations of lapatinib significantly enhance the cytotoxic effects of doxorubicin in MCF-7 cells, whereas FTC does not significantly enhance the cytotoxic effects of doxorubicin in MCF-7 cells (Table 1). To determine whether the relative lack of cytotoxicity produced by lapatinib is related to the expression of EGFR and/or Her-2, we used flow cytometry to detect EGFR and Her-2 in MCF-7 and S1 cell lines (Fig. 3B). Calu-3, a positive control cell line, expressed relative high levels of both EGFR (66.6 ± 2.8%) and Her-2 (97.5 ± 1.2%). The expression level of EGFR in S1 cells (65.0 ± 4.9%) is significantly higher than that in S1-M1-80 cells (37.6 ± 2.5%), whereas the expression level of Her-2 in S1 cells (29.3 ± 3.1%) is significantly lower than that in S1-M1-80 cells (49.3 ± 6.6%). MCF-7 cell expressed low levels of EGFR (10.8 ± 2.7%), whereas the MCF-7/adr cell line showed high expression (65.0 ± 4.5%). However, the MCF-7 (28.8 ± 2.2%) and MCF-7/adr (8.2 ± 0.5%) cell lines expressed low levels of Her-2. These results indicated that lapatinib potentiates the cytotoxic effects of anticancer drugs independent of the level of EGFR and Her-2 expression. Furthermore, we tested whether the concentrations of lapatinib that we used in our experiments can inhibit the phosphorylation of Akt and Erk1/2. As shown in Fig. 3A, lapatinib did not significantly block the phosphorylation of Akt and Erk1/2 in any of the four cell sublines. This result suggested that lapatinib-induced enhancement of the cytotoxicity of chemotherapeutic agents in MCF-7, MCF-7/adr, S1, and S1-M1-80 cells is not due to its antagonism of EGFR and Her-2 receptors.

**Effect of lapatinib on the expression of mRNA and protein levels of ABCB1 and ABCG2.** The reversal of ABC transporter-mediated MDR can be achieved either by decreasing transporter expression or by inhibiting function. Therefore, we determined the effect of lapatinib on the expression level of mRNA and protein levels using reverse transcription-PCR (RT-PCR) and Western blot, respectively. Our results showed that no marked difference in ABCB1 or ABCG2 expression at the mRNA (Fig. 3C) or protein level (Fig. 3D) was observed in MCF-7/adr cells (top) or S1-M1-80 cells (bottom) treated with lapatinib for 48 h compared with untreated cells. These results provide evidence that lapatinib does not affect the expression of ABCB1 and ABCG2. Thus, it mediates the reversal of MDR by inhibiting the function of ABCB1 and ABCG2.

**Lapatinib reverses ABCB1-mediated MDR in vivo.** We examined the efficacy of lapatinib in vivo to reverse the resistance to paclitaxel using established KBv200 cell xenografts in nude mice. There was no significant difference in tumor size between animals treated with saline, lapatinib, or paclitaxel alone. However, the

---

**Figure 3.** The effect of lapatinib on blockade of Akt and Erk1/2 phosphorylation (A), the expression level of EGFR and Her-2 (B), the expression of ABCB1 and ABCG2 genes (C), and the expression level of ABCB1 and ABCG2 protein (D). In A, equal amount of protein from various cells was loaded for Western blot as described in Materials and Methods. In B, Calu-3 cells were used as a positive control of EGFR-expressing and Her-2–expressing cells. Flow cytometric analysis was performed as described in Materials and Methods. In C, MCF-7/adr and S1-M1-80 cells were treated by lapatinib of various concentrations for 48 h. The mRNA levels of ABCB1 and ABCG2 were determined by RT-PCR as described in Materials and Methods. In D, MCF-7/adr and S1-M1-80 cells were treated by lapatinib of various concentrations for 48 h. Equal amounts of total cell lysates were used for loading and detected by Western blotting as described in Materials and Methods. All these experiments were repeated at least thrice, and a representative experiment is shown in each panel.
combination of lapatinib and paclitaxel produced a significant greater inhibitory effect on tumor growth compared with animals treated with only saline, paclitaxel, or lapatinib ($P < 0.05$; Fig. 4) and the inhibition rate was 50.1%. In addition, at the doses tested, no mortality or significant decrease in body weight was associated with the combination treatments, suggesting that the combination regimen did not result in increased toxicity.

**Discussion**

Lapatinib is an inhibitor of the intracellular tyrosine kinase domains of both the EGFR and Her-2 receptors. Mutations or dysregulation in these receptors has been shown to play a role in the development of certain cancers. Lapatinib was approved for use in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors over-expressed Her-2 and who had received prior therapy with an anthracycline, a taxane, and trastuzumab. As the new TKIs are being introduced into the clinic, a significant effort will be directed toward increasing the anticancer activity of conventional chemotherapeutic agents or restoring chemosensitivity of resistant cancer cells to conventional chemotherapeutic agents. Our results showed for the first time that lapatinib had potent reversing activity in both ABCB1- and ABCG2-overexpressing MDR cells in vitro. Lapatinib, however, had no significant reversal effect in ABCC4-overexpressing NIH3T3/ABCC4-2 cells and lung cancer-resistant protein–overexpressing SW1573/2R1220 cells. Although lapatinib slightly enhanced the cytotoxicity of doxorubicin, mitoxantrone, and topotecan in drug-sensitive MCF-7 and S1 cells, respectively, lapatinib significantly potentiated the cytotoxicity of conventional chemotherapeutic agents in ABCB1- and ABCG2-overexpressing MDR cells to a much greater extent. Furthermore, lapatinib did not significantly alter cellular sensitivity to non-ABCB1 or non-ABCG2 substrates. Although the concentrations of lapatinib used in the current study (up to 2.5 μmol/L for MCF-7 and S1 cells) have been reported to be sufficient to block the EGFR signaling pathway, we did not observe any significant effect on the growth and survival of cells (Supplementary Fig. S1 and S2). In addition, we found that 2.5 μmol/L lapatinib does not block the phosphorylation of Akt and Erk1/2 (Fig. 3A) in MCF-7 and S1 cell lines. Thus, the potentiation of the cytotoxic effects of doxorubicin by lapatinib in MCF-7 cells may not be related to the antagonism of EGFR or Her-2 receptors. It is possible that this effect may be generated by a nonspecific cytotoxic mechanism or other unknown action of the drug. To determine if the in vitro effects of lapatinib can be extended to an in vivo paradigm, we have examined the effect of lapatinib on the antitumor activity of paclitaxel in xenograft model in mouse. Indeed, our results indicated that the combination of lapatinib with paclitaxel results in markedly enhanced antitumor activity of paclitaxel in an ABCB1-overexpressing tumor xenograft model (Fig. 4A and B).

Our results suggest that lapatinib significantly potentiated the toxicity of established ABCB1 or ABCG2 substrates in ABCB1- or ABCG2-overexpressing MDR cells unrelated to its inhibitory action of tyrosine kinase. Several groups have published in vitro data that support our findings. Coley and colleagues (36) reported that the addition of GW282974A, an analogue of lapatinib, to

---

Figure 4. Potentiation of antitumor effects of paclitaxel by lapatinib in a xenograft model of KBv200 cells in athymic nude mice. The experiment was carried out using athymic mice implanted s.c. with KBv200 cells. A, changes in tumor volume with time. Points, mean tumor volume for each group in 10 to 11 mice after implantation; bars, SD. B, tumor sizes. The picture was taken on the 17th day after implantation. The doses were as follows: lapatinib (100 mg/kg, p.o., q3d × 4) and paclitaxel (18 mg/kg, i.p., q3d × 4) + lapatinib (100 mg/kg, p.o., q3d × 4, given 1 h before paclitaxel administration).

5 Unpublished data.
paclitaxel resulted in a synergistic inhibition of cell survival in ABCB1-expressing human ovarian cancer cell line PE01TaxR. The dual EGFR and Her-2 directed small-molecule TKI CI1033 enhanced the uptake and cytotoxicity of SN-38 and topotecan in ABCG2-expressing glioblastoma T98G cells, colorectal carcinoma HCT8 cells, and ABCG2-transfected MDA-MB-231 cells (37). Recently, Polli and colleagues (38) reported that lapatinib is a substrate of ABCB1 and ABCG2 and an inhibitor of ABCB1 and ABCG2 (IC50 values of 3.9 and 0.025 μmol/L, respectively). Their results are not only consistent with our findings that lapatinib is an inhibitor of ABCB1 and ABCG2, but their data are also in agreement with our findings that low concentrations of lapatinib are able to stimulate the ATPase activity of ABCG2 (Fig. 2A and B) and inhibit the photolabeling of ABCB1 and ABCG2 with IAAP (Fig. 2C and D), indicating that lapatinib directly interacts with these transporters. Taken as a whole, these data suggest that the pharmacokinetics of conventional chemotherapeutic agents that are affected by ABC transporters may be altered in the presence of lapatinib.

Clinical studies have also hinted at interactions between lapatinib and ABC transporters. Lapatinib has been shown to have clinical benefit in patients with brain-metastasized breast cancer, increasing drug penetration across the blood-brain barrier, presumably via inhibition of ABCB1 (37). The combination of lapatinib and tamoxifen and ABCB1 substrate or conventional chemotherapeutic agents, such as paclitaxel and docetaxel, may be active against hormone-refractory and chemotherapeutic drug-resistant metastasized breast cancer (14, 39–41). In the phase I study, when compared with irinotecan alone, the coadministration of lapatinib and irinotecan significantly increased the area under the plasma concentration-time curve of SN-38, the active metabolite of irinotecan, which is an ABCB1 and ABCG2 substrate (42). Despite the aforementioned promising findings, the authors of these articles did not propose any clear mechanisms to explain the synergy between lapatinib and chemotherapeutic agents. However, in human pharmacokinetic studies, the highest peak plasma lapatinib level was ~3 μmol/L, the half-life was ~17 h, and steady-state concentrations were achieved after 6 to 7 days of once-daily dosing (43, 44). These data suggest that the in vitro concentrations of lapatinib used in our experiments are similar to those obtained in plasma after therapeutic treatment. Thus, it is possible that lapatinib affects chemosensitivity of refractory or resistant cancer cells through its interaction with ABC transporters.

Recently, Cusatis and colleagues (45) reported that one common functional single-nucleotide polymorphism in the ABCG2 gene, ABCG2 421C→A (Q141K), is associated with diarrhea, a gefitinib-induced adverse effect, and led to a high risk of diarrhea in patients treated with oral gefitinib. The same group also reported that this functional variant of ABCG2 was associated with a greater accumulation of gefitinib at steady state and this may be relevant to toxicity and antitumor activity of EGFR TKIs (46). These findings suggest that the functional variants of ABCG2 in patients may affect the pharmacokinetics and pharmacodynamics of not only established ABCG2 substrates, such as camptothecins and mitoxantrone, but also novel molecular target anticancer drugs, such as gefitinib and lapatinib. Therefore, these functional single-nucleotide polymorphisms can cause alterations in the adverse events and therapeutic effects of chemotherapy. Similar to gefitinib, the most frequent adverse effects of lapatinib in patients are skin rash and diarrhea (47). Thus, these functional single-nucleotide polymorphisms of ABCG2 in patients may also affect the pharmacokinetics and pharmacodynamics of lapatinib, resulting in an attenuation of its adverse events and therapeutic effects.

The expression of the Arg482, Gly482, and Thr482 variant forms of ABCG2 has been shown to confer greater resistance to some substrates, such as mitoxantrone, and the sensitivity to some ABCG2 modulators is decreased compared with the wild-type form (48–50). Our results showed that lapatinib significantly enhances the sensitivity of ABCG2 substrates not only in cells overexpressing wild-type but also in the R482G/T variants of ABCG2. Mechanistically, similar to other MDR inhibitors, lapatinib may be able to reverse ABCB1- or ABCG2-mediated drug resistance by inhibiting drug efflux. Consistent with this hypothesis, we found that incubating MDR cells (such as MCF-7/adr and S1-M1-80 cells) concomitantly with conventional chemotherapeutic drugs (substrates of ABC transporters) and lapatinib resulted in a higher intracellular drug accumulation in ABCB1- and ABCG2-expressing cells than cells incubated with drug alone (Fig. 1A and B). A similar result was obtained when we examined accumulation of rhodamine 123 in ABCB1-expressing cells (data not shown). Furthermore, the transport of Etop 17G and methotrexate inhibited by lapatinib in a concentration-dependent manner in membrane vesicles overexpressed wild-type ABCG2. However, the majority of substrates that interact with the ABC drug transporters stimulate ATP hydrolysis, and the fact that lapatinib stimulated the ATP hydrolysis of both ABCB1 and ABCG2 suggested that it behaved similarly to other known substrates of these transporters. These data led us to speculate that lapatinib interacts directly with the transporters. Indeed, this was confirmed by the finding that lapatinib significantly inhibited the binding of the compound IAAP, which photolabels the drug substrate–binding site of ABCB1 and ABCG2. Lapatinib, however, had no significant effect on the expression of ABCB1 in MCF-7/adr cells and ABCG2 in S1-M1-80 cells (Fig. 3C and D). These results suggested that lapatinib reverses ABCB1- and ABCG2-mediated MDR by inhibiting the function as opposed to expression of these two pumps. The expression of EGFR and Her-2 (Fig. 3A) did not significantly alter lapatinib toxicity in MCF-7/adr and S1-M1-80 cells or parental MCF-7 and S1 cells (Supplementary Fig. S1). Additional in vitro studies in cell lines expressing wild-type and mutant EGFR may be useful to determine if there is a difference in the efficacy between tumors expressing wild-type or mutant EGFR. The observed toxicity of lapatinib at such relatively high concentrations may be generated by a non-EGFR phosphorylation pathway. However, in this study, we did not examine the potential mechanisms of lapatinib toxicity in our cell lines.

In conclusion, lapatinib may inhibit cellular ABCB1 and ABCG2 functions at clinically relevant concentrations. The inhibition of drug efflux as a result of direct interaction of lapatinib with ABCB1 or ABCG2 may lead to increased clinical response when combined with conventional chemotherapeutic agents. Our analysis of the reversal effect of lapatinib in tumor xenograft model indicates that combination of lapatinib with other anticancer drugs may be important in surmounting clinical resistance in cancer chemotherapy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Susan E. Bates (National Cancer Institute, NIH) for S1 and S1-M1-80 cells and FTC, Dr. Somnath Pal (St. John’s University) for assistance with statistical analyses. Dr. Jian-Zhang (Sun Yat-sen University) for technical assistance, and Tong Shen (St. John’s University) and Yaungn (Mimi) Chen (Montgomery High School, Skillman, NJ) for editorial assistance with the manuscript.

References

Cancer Research

Cancer Res 2008; 68: (19), October 1, 2008

7914

www.aacrjournals.org

Downloaded from cancerres.aacrjournals.org on July 22, 2017. © 2008 American Association for Cancer Research.
Correction: Reversal of Multidrug Resistance by Lapatinib

In the article on reversal of multidrug resistance by lapatinib in the October 1, 2008 issue of Cancer Research (1), there is an error in Fig. 1A. The corrected figure appears below.

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/19/7905

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2008/10/06/68.19.7905.DC1
http://cancerres.aacrjournals.org/content/suppl/2008/10/06/68.19.7905.DC2

Cited articles
This article cites 50 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/19/7905.full#ref-list-1

Citing articles
This article has been cited by 25 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/68/19/7905.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.